On October 6, 2008, Salix Pharmaceuticals, Ltd. issued a press release announcing the successful completion and outcome of its pivotal Phase 3 trial to evaluate the efficacy, safety and tolerability of rifaximin in preventing hepatic encephalopathy. A copy of this press release is attached as Exhibit 99.1.

On October 6, 2008, the company also issued a press release announcing that it presented at the annual meeting of the American College of Gastroenterology results from a phase II chemical trial that demonstrate the clinical utility of rifaximin in treating patients with irritable bowel syndrome (IBS). A copy of this press release is attached as Exhibit 99.2.

On October 7, 2008, the company issued a press release announcing data that demonstrates that mesalamine granules maintained remission in ulcerative colitis patients who switched from another 5-ASA product. A copy of this press release is attached as Exhibit 99.3.

(d) Exhibits

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.